[go: up one dir, main page]

MX2024001374A - Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease. - Google Patents

Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease.

Info

Publication number
MX2024001374A
MX2024001374A MX2024001374A MX2024001374A MX2024001374A MX 2024001374 A MX2024001374 A MX 2024001374A MX 2024001374 A MX2024001374 A MX 2024001374A MX 2024001374 A MX2024001374 A MX 2024001374A MX 2024001374 A MX2024001374 A MX 2024001374A
Authority
MX
Mexico
Prior art keywords
celiac
celiac disease
treatment
methods
refractory
Prior art date
Application number
MX2024001374A
Other languages
Spanish (es)
Inventor
Francisco Leon
Wayne H Tsuji
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2024001374A publication Critical patent/MX2024001374A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Methods and pharmaceutical compositions are provided herein for the treatment of inflammatory disorders, in particular celiac disease, refractory celiac disease and non-celiac gluten sensitivity.
MX2024001374A 2016-06-15 2016-06-15 Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease. MX2024001374A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/037708 WO2017217985A1 (en) 2016-06-15 2016-06-15 Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease

Publications (1)

Publication Number Publication Date
MX2024001374A true MX2024001374A (en) 2024-02-27

Family

ID=56292925

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018015363A MX2018015363A (en) 2016-06-15 2016-06-15 Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease.
MX2024001374A MX2024001374A (en) 2016-06-15 2016-06-15 Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018015363A MX2018015363A (en) 2016-06-15 2016-06-15 Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease.

Country Status (11)

Country Link
EP (1) EP3472202A1 (en)
JP (2) JP2019521981A (en)
CN (1) CN109311972A (en)
AR (1) AR108790A1 (en)
AU (2) AU2016411388A1 (en)
BR (1) BR112018076287A2 (en)
CA (1) CA3020894A1 (en)
EA (1) EA201892707A1 (en)
MX (2) MX2018015363A (en)
TW (2) TW202327653A (en)
WO (1) WO2017217985A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017382850B2 (en) * 2016-12-21 2024-11-21 Cephalon Llc Antibodies that specifically bind to human IL-15 and uses thereof
WO2020089396A2 (en) * 2018-10-31 2020-05-07 Tiziana Life Sciences Plc Composition and methods of treating inflammatory and autoimmune diseases
UY39896A (en) 2021-08-12 2023-02-28 Amgen Inc ANTIBODY FORMULATIONS
WO2024028448A1 (en) 2022-08-04 2024-02-08 Calypso Biotech Sa Il-15 inhibitors useful for the treatment of atopic dermatitis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
JP4892335B2 (en) * 2003-02-26 2012-03-07 ゲンマブ エー／エス Human antibody specific for interleukin-15 (IL-15)
SG172855A1 (en) * 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
WO2011031986A1 (en) * 2009-09-10 2011-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health Assays for soluble il-15 receptor alpha
EP2963057A1 (en) * 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15

Also Published As

Publication number Publication date
TW202327653A (en) 2023-07-16
CA3020894A1 (en) 2017-12-21
JP2019521981A (en) 2019-08-08
MX2018015363A (en) 2019-04-15
EP3472202A1 (en) 2019-04-24
BR112018076287A2 (en) 2019-03-26
AU2024205264A1 (en) 2024-08-22
CN109311972A (en) 2019-02-05
AU2016411388A1 (en) 2018-11-08
WO2017217985A1 (en) 2017-12-21
EA201892707A1 (en) 2019-05-31
JP2022001577A (en) 2022-01-06
TW201803591A (en) 2018-02-01
AR108790A1 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
NZ731789A (en) Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12018500586B1 (en) Farnesoid x receptor agonists and uses thereof
EP4378536A3 (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP4620519A3 (en) Methods and compositions relating to chondrisomes from blood products
MD20170032A2 (en) Anti-TIGIT antibodies
NZ737399A (en) Ccr2 modulators
MX2017015574A (en) Inhibitors of bruton's tyrosine kinase.
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2017009417A (en) Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof.
NZ723884A (en) Methods of treating alzheimer’s disease
MX2017002489A (en) Human therapeutic agents.
EA201791937A1 (en) ANTI-INFLAMMATORY POLYPEPTIDES
PH12017500602A1 (en) Methods for treating ocular conditions
ZA201807438B (en) Methods of treating ocular conditions
MX382092B (en) Heterocyclic compounds for the treatment of disease
TW201713323A (en) Therapeutic compositions and methods of use thereof
MX2024001374A (en) Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease.
JOP20190164B1 (en) Compositions and methods for treating farber disease
MX370897B (en) Fused bicyclic compounds for the treatment of disease
EP4218789A3 (en) Compositions for colon cleansing and the treatment of gastrointestnal disorders
PH12017501979A1 (en) Pharmaceutical compound
MX2018014034A (en) Fused bicyclic compounds for the treatment of disease.